Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 55 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Induction Lorlatinib in Stage III Non-small Cell Lung CancerActive, not recruitingNCT05740943Phase 2
• To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDSStatus unknownNCT05740917Phase 1
• Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisActive, not recruitingNCT05739435Phase 2
• Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsActive, not recruitingNCT05735834Phase 3
• Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaActive, not recruitingNCT05734495Phase 2
• A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingNCT05734105Phase 3
• HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyCompletedNCT05720767Phase 1
• Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Not applicable
• Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyActive, not recruitingNCT05718869Phase 2
• Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerWithdrawnNCT05718297Phase 2
• Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male VolunteersCompletedNCT05716126Phase 1
• A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingNCT05716087Phase 2
• Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Phase 2
• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyActive, not recruitingNCT05707377Phase 2/3
• Lazertinib 160mg in EGFR T790M NSCLCStatus unknownNCT05701384Phase 2
• Janus Kinase Inhibition in SarcoidosisCompletedNCT05696795Phase 2
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCompletedNCT05695950Phase 2
• Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic RetinopathyActive, not recruitingNCT05695417Phase 1
• Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerWithdrawnNCT05693090Phase 1
• A Study of PBI-200 With Ritonavir or Cobicistat in Healthy VolunteersCompletedNCT05692570Phase 1
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedNCT05691478Phase 2/3
• A Formulation Bridging and Food Effect Study of PBI-200 in Healthy VolunteersCompletedNCT05690932Phase 1
• Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal CancerWithdrawnNCT05690035Phase 2
• VTX958 for the Treatment of Moderately to Severely Active Crohn's DiseaseTerminatedNCT05688852Phase 2
• Use of Baricitenib to Maintain of RemissionStatus unknownNCT05686746Phase 2/3
• Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT05682170Phase 1/2
• Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05678673Phase 3
• Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05677919Phase 2
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive, not recruitingNCT05677451Phase 3
• Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingNCT05672316Phase 1/2
• Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingNCT05672173Phase 2
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Phase 3
• A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsCompletedNCT05665283Phase 1
• Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host DiseaseCompletedNCT05663827Phase 3
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
• A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung CancerTerminatedNCT05662670Phase 1/2
• Therapies for Down Syndrome Regression DisorderCompletedNCT05662228Phase 2
• Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CompletedNCT05660954Phase 2
• Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy SubjectsStatus unknownNCT05660720Phase 1
• Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid ArthritisCompletedNCT05660655Phase 4
• Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint InhibitorsWithdrawnNCT05660421Phase 2
• Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1
• VTX958 Versus Placebo for the Treatment of Moderate to Severe PsoriasisTerminatedNCT05655299Phase 2
• A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or FusionsActive, not recruitingNCT05653869Phase 1
• ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruitingNCT05650879Phase 1
• A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.TerminatedNCT05644600Phase 1
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular CarcinomaActive, not recruitingNCT05644379Phase 1
• Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous LeukemiaStatus unknownNCT05638763Phase 2
• Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionCompletedNCT05636293Phase 2
• Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine AdhesionsStatus unknownNCT05635071Phase 2/3
• Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedNCT05631678Phase 1
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingNCT05629234Phase 3
• Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid TumorsActive, not recruitingNCT05627063Phase 1
• Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaActive, not recruitingNCT05625737Phase 2
• Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on HemodialysisCompletedNCT05624723Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedNCT05624710Phase 1
• A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingNCT05624554Phase 3
• De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisActive, not recruitingNCT05622318Phase 2
• Dose-escalation of Regorafenib in Advanced Hepatocellular CarcinomaActive, not recruitingNCT05622136Phase 2
• HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05620836Phase 3
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT05620823Phase 3
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsCompletedNCT05615012Phase 1
• Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyWithdrawnNCT05614453Phase 2
• Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor SubjectsStatus unknownNCT05610202Phase 1
• Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Active, not recruitingNCT05607550Phase 3
• To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 WeeksStatus unknownNCT05606107Phase 4
• Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCTWithdrawnNCT05604755Phase 2
• Anlotinib and Radiotherapy in Resectable Soft Tissue SarcomaStatus unknownNCT05602415Phase 2
• Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabCompletedNCT05602207Phase 4
• Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingNCT05601973Phase 2
• Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruitingNCT05593094Phase 1/2
• Drug-drug Interaction Study of XZP-3621 TabletStatus unknownNCT05586568Phase 1
• Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Phase 2
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloCompletedNCT05583526Phase 3
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2
• A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCompletedNCT05579574Phase 1
• HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedNCT05571787Phase 1
• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingNCT05567185Phase 1
• Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET AlterationsWithdrawnNCT05567055Phase 2
• Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/RearrangementsTerminatedNCT05565794Phase 2
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
• Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
• A Trial of DDI Between SHR1459 and Efavirenz With Healthy SubjectsCompletedNCT05560360Phase 1
• Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction PatientsStatus unknownNCT05559242Phase 1
• TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2
• Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
• Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Status unknownNCT05549284Phase 2
• Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy AdultsCompletedNCT05547399Phase 1
• Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2
• Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)Active, not recruitingNCT05546580Phase 1
• A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCompletedNCT05546151Phase 1
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2

← Tyrosine Kinase Inhibitors overview